FDA Approves First Rapid-Acting Insulin Biosimilar For Diabetes

The U.S. Food and Drug Administration (FDA) approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. Merilog is marketed by Sanofi-Aventis U.S. LLC. This is the first rapid-acting insulin biosimilar product approved by the FDA, and the third insulin biosimilar approved by the FDA.

Merilog is a rapid-acting human insulin analog. It helps to lower mealtime blood sugar spikes to improve control of blood sugar in people with diabetes. The approval is for both a 3 milliliter (mL) single . . .